MBX Biosciences, Inc.
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 18.71% | -53.21% | 14.09% | -14.41% | -28.53% |
| Total Depreciation and Amortization | -20.78% | 32.76% | -22.67% | 19.05% | 31.25% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 90.10% | 344.92% | -81.33% | 25.15% | -55.90% |
| Change in Net Operating Assets | 53.00% | 195.69% | -122.63% | 37.25% | 365.21% |
| Cash from Operations | 23.12% | -41.41% | -9.36% | -10.50% | -23.90% |
| Capital Expenditure | -2,256.67% | 67.39% | -61.40% | 87.39% | -65.57% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 719.81% | 104.84% | 33.24% | -1,254.09% | -147.38% |
| Cash from Investing | 705.52% | 104.79% | 33.18% | -1,177.25% | -151.14% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 33,050.00% | -97.95% | -99.89% | 348,922.00% | -73.54% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -100.00% | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 85.12% | -21.31% | -30,083.33% |
| Cash from Financing | 33,050.00% | 103.03% | -100.06% | 13,490.91% | -1,062.30% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 150.79% | 76.71% | -169.39% | 625.09% | -567.61% |